Jun 12, 2023 / 03:40PM GMT
Ziyi Chen - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Thank you for joining this session, this session with BeiGene. And this is Ziyi Chen, China healthcare analyst at Goldman Sachs. So here today we have Mark and Julia, Chief Medical Officer, Solid Tumors and also CFO of the company, join us to discuss the recent updates at BeiGene. I think you guys just come back from ASCO. Tell us a bit more about what has been the reception of the data at ASCO and any key takeaways from the ASCO.
Mark Lanasa - BeiGene, Ltd. - Senior VP & Chief Medical Officer for Solid Tumors
Great. Thank you all for joining today. Very glad to be here again. My name is Mark Lanasa. So we had a very busy and exciting ASCO annual meeting, I guess. I would touch on 3 different components. So first, there was a lot of data related to TIGIT. We shared data from a Phase I study, an expansion in gastroesophageal cancer where we showed incremental improvement in response rate. And, of course, there was a lot of interest both in the Roche data in HCC as well as in the Arcus
Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers